Acute Care
Reports of severe illness among children are mounting, requiring more urgent research into susceptibility and possible treatments.
While it hasn't yet been tested in humans, its ability to target multiple coronaviruses shows early promise.
Many have but back on healthcare visits or are planning to do so, and a substantial number are considering curbing medication spending.
Hydroxychloroquine can reduce inflammation, pain and swelling, but mild to moderate COVID patients showed more adverse events when treated with it.
Some stroke patients may fear contracting the coronavirus, while others who are isolated may not be discovered quickly enough.
The treatment may reduce the risk to healthcare workers because it reduces the duration and quantity of viral shedding.
Gilead Sciences committed to supplying approximately 607,000 vials over the next six weeks to treat an estimated 78,000 hospitalized patients.
One promising candidate is remdesivir, a drug originally developed for Ebola, which the FDA has approved for emergency use during the pandemic.
The test could detect COVID-19 infections in about six out of 10 people, and was nearly perfect in determining when an infection wasn't present.
Patient and staff morale has improved following implementation of a personalized, virtual rounding program intended to foster connectedness.